ClinicalTrials.gg
TerminatedNCT03476993Updated Oct 11, 2019

Non-comparative Study of BCD-085 in Combination With UDCA in Patients With Primary Biliary Cholangitis

A Phase 2 interventional study of BCD-085 in Liver Cirrhosis, Biliary, sponsored by Biocad. Terminated at 3 sites in Russian Federation. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-10-11.

Sponsored by Biocad · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponosor's decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 60 Years
Sex
All
01

Study summary

BCD-085 is an innovative drug, anti-interleukin-17 monoclonal antibody. The aim of the study is to evaluate the efficacy and safety of BCD-085 in patients with primary biliary cholangitis (PBC).

Read the detailed description

This is an open-label proof-of-concept phase 2A study. The aim of the study is to evaluate the efficacy and safety of BCD-085 in combination with ursodeoxycholic acid in patients with primary biliary cholangitis (PBC) with compensated liver function with an inadequate (suboptimal) response to ursodeoxycholic acid.

In this study the inadequate (suboptimal) response to ursodeoxycholic acid (UDCA) is defined as screening alkaline phosphatase (ALP) level > 1.67 ULN (the upper limit of normal) despite treatment with UDCA in stable dose for at least 6 months before signing the ICF.

02

Conditions studied

  • Liver Cirrhosis, Biliary

Keywords

  • primary biliary cholangitis
  • IL-17 monoclonal antibody
03

In context

Liver Cirrhosis, Biliary

214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.

This study's enrollment of 9 is below the median of 60 across 151 interventional studies indexed under Liver Cirrhosis, Biliary.

Browse Liver Cirrhosis, Biliary studies →

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Singed form (ICF)
  2. Men and women, age 18 - 80 years at the time of signing the ICF
  3. Established diagnosis of PBC with following criteria (according to EASL 2017 guidelines):

    • documented ALP elevation
    • documented АМА ≥ 1:40 or PBC-specific ANА (anti-sp100/anti-gp210).
  4. Suboptimal response to ursodeoxycholic acid (UDCA) taken in stable dose for at least 6 months before signing ICF with screening alkaline phosphatase (ALP) level > 1.67 (the upper limit of normal)
  5. Fertile patients and their partners agree to use barrier throughout the study and 4 weeks after its completion.

Exclusion criteria

Exclusion Criteria:

  1. History of gastrointestinal bleeding, hepatic encephalopathy or ascites requiring treatment with diuretics.
  2. MELD ≥ 15, history of liver transplantation, staying in the Liver Transplant Waiting List.
  3. Established diagnosis of hepatocellular carcinoma (HCC), hepatorenal syndrome.
  4. Direct > 1.0 mg/dL at screening.
  5. Documented diagnosis: nonalcoholic steatohepatitis, hepatitis, primary sclerosing cholangitis, alcoholic liver disease, Gilbert's syndrome, Wilson disease, hemochromatosis, alfa-1-antitrypsin deficiency.
  6. , , or syphilis.
  7. Use of colchicine, methotrexate, azathioprine or systemic within 3 months before signing the ICF.
  8. Previous use of monoclonal antibodies targeting IL17 or its receptor.
  9. Vaccination with live or attenuated vaccines within 8 weeks before signing the ICF.
  10. Any active systemic infection or recurrent infection at screening or 30 days before signing the ICF.
  11. Established diagnosis of chronic disease (e.g. sepsis, invasive mycosis, histoplasmosis etc.) that may increase the risk of infectious adverse events during the study.
  12. Severe infections (including those that required hospitalization or parenteral antibacterial/antimycotic/antiprotozoal treatment) within 6 months before signing the ICF
  13. Established diagnosis of herpes zoster infection (or history of herpes zoster infection).
  14. latent tuberculosis infection (positive results of the Diaskintest or QuantiFERON test, or T-spot).
  15. Concurrent diseases at screening that may increase the risk of adverse events during the study or affect the evaluation of PBC symptoms (mask, enhance or alter the symptoms of PBC, or cause clinical or laboratory signs/symptoms similar to those of PBC)
  16. Known allergy or intolerance to monoclonal antibody drugs (murine, chimeric, humanized, or human) or any other components of BCD-085.
  17. Pregnancy, breastfeeding or planning of pregnancy during the study.
  18. Any psychiatric conditions including severe depressive disorders and/or any history of suicidal thoughts or suicidal attempts that may constitute the excessive risk for the patient or that may affect the patient's ability to follow the protocol.
  19. Alcohol or substance abuse.
  20. Participation in other clinical trials within less than 90 days before signing the ICF.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    BCD-085

    All patients will receive BCD-085 (subcutaneous injection) in combination with ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day

    Biological: BCD-085

Interventions

  • BiologicalBCD-085

    All patients will receive BCD-085 (subcutaneous injections) once a week during the period of induction of remission, then once every 2 weeks during the period of remission maintenance and then once every 4 weeks during the period of accumulation of treatment effect. All patients will receive ursodeoxycholic acid (UDCA) in standard dose 13-15 mg/kg/day.

06

What researchers measure

Primary outcomes

  1. The proportion of patients with alkaline phosphatase (ALP) decrease > 40% from Baseline (day 1 week 0) or with normal ALP level (Barcelona criteria) after 24 weeks of treatment with BCD-085 in combination with UDCA.

    Biochemical response is defined as ALP decrease \> 40% from Baseline or normalisation of ALP level (Barcelona criteria).

    Time frame: week 24

07

Study locations

3 sites
  • State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University
    Moscow, Russian Federation
  • North-Western State Medical University named after I.I. Mechnikov
    Saint Petersburg, Russian Federation
  • Smolensk state medical university
    Smolensk, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jul 2019, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
Mar 26, 2018
StartActual
Apr 27, 2018
Primary completionActual
Jul 1, 2019
CompletionActual
Jul 1, 2019
Last update
Oct 11, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03476993
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Mar 26, 2018
Start date
Apr 27, 2018
Primary completion
Jul 1, 2019
Completion
Jul 1, 2019
Last update
Oct 11, 2019

Study contacts

Marina Maevskaya
principal investigator · State Budgetary Higher Vocational Education Institution I.M. Sechenov First Moscow State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BCD-085

Start the discussion